Oncology
Gestational Trophoblastic Neoplasm
11
Pipeline Programs↗
0
Active Trials↗
9
Companies Involved↗
Gestational Trophoblastic Neoplasm is an emerging landscape with 11 programs across 9 companies. The most active players are Gynecologic Oncology Group, Glaxo Dba Glaxosmithkline, Merck & Co.. 3 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 27
Analysis
Modality Breakdown
12programs
Small molecule758%
Monoclonal antibody542%
Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
2
clinical trials
Unknown status2 · 100%
Clinical Trials
Trial Activity
Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6
Unknown status·WWomen's Hospital School Of Medicine Zhejiang University·Phase 2/3·NCT03885388·300 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)